RxDoctor Payments Data

Lauren Lutz, NP

Psychiatric/Mental Health · Columbus, INNPI 1417407743

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $262,886 of the $319,934 with a category attached, or 82.2%. 28 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 40.7% of the total. Among psychiatric/mental health clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$319,934in general payments, 2019–2025

Across 967 payments — averaging $330.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$130K
  • AbbVie$69K
  • Axsome Therapeutics, Inc.$42K
  • Neurocrine Biosciences, Inc.$29K
  • Alkermes, Inc.$23K
  • Johnson & Johnson$9K
  • plus $18K from 22 others

What the payments were for

  • Consulting fees$19,1846%
  • Speaking & faculty fees$262,88682%
  • Travel & lodging$23,5197%
  • Food & beverage$14,0374%
  • Education$3090%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$319,934 in reported general payments places this provider in the 95th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$2,781
Medicare patients
20
Services billed
44

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate49$375,832
RexultiBrexpiprazole130$242,607
Invega SustennaPaliperidone Palmitate60$210,852
Abilify AsimtufiiAripiprazole27$156,191
VraylarCariprazine Hcl86$152,060
CaplytaLumateperone Tosylate91$150,698
AustedoDeutetrabenazine12$143,422
Invega TrinzaPaliperidone Palmitate13$120,982
Abilify MaintenaAripiprazole29$82,868
AuvelityDextromethorphan Hbr/Bupropion63$81,023
AristadaAripiprazole Lauroxil24$77,247
TrintellixVortioxetine Hydrobromide91$74,277
Paliperidone ErPaliperidone63$46,651
FanaptIloperidone12$42,903
Risperdal ConstaRisperidone Microspheres24$31,778

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Asimtufii, Abilify Maintena$787$481,666186 claims
Neurocrine Biosciences, Inc.Ingrezza$29,121$375,83249 claims
Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta$9,418$363,61297 claims
AbbVieVraylar, Fetzima$68,789$157,79498 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$130,122$150,69891 claims
Teva Pharmaceuticals USA, Inc.Austedo$361$143,42212 claims
Axsome Therapeutics, Inc.Auvelity$41,635$81,02363 claims
Alkermes, Inc.Aristada$22,675$77,24724 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$64$74,27791 claims
Vanda Pharmaceuticals Inc.Fanapt$6,598$42,90312 claims
Supernus Pharmaceuticals, Inc.Qelbree$683$7,71015 claims
Lilly USA, LLCOlanzapine$21$7,175104 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in Columbus

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →